Loading...
01/11 11:05
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary presents a mixed picture: strong revenue growth and optimistic guidance, particularly for NUPLAZID, contrast with increased R&D and SG&A expenses. The absence of a share repurchase program and unresolved regulatory and competitive challenges add uncertainty. The Q&A section reveals confidence in future pricing and product success, but also highlights risks in regulatory approval and market competition. Given the market cap of approximately $2.7 billion, the overall sentiment suggests a neutral stock price movement in the near term.
Total Revenue $244.3 million, up 19% year-over-year.
DAYBUE Net Product Sales $84.6 million, up 11% year-over-year, driven by an all-time high in unique patients receiving shipments.
NUPLAZID Net Product Sales $159.7 million, up 23% year-over-year, with 6% attributable to volume and a one-time change in gross to net due to Medicare Part D redesign.
R&D Expenses $78.3 million, up from $59.7 million year-over-year, due to increased spending on clinical stage programs.
SG&A Expenses $126.4 million, up from $108 million year-over-year, primarily driven by the continuation of the NUPLAZID consumer activation campaign and higher commercial operation expenses.
Cash Balance $681.6 million as of March 31.
Cash Flow from Operating Activities Positive in the quarter, but cash declined sequentially due to $98.8 million in payments made to Neuren.
DAYBUE Sales: Generated $84.6 million in DAYBUE sales in Q1 2025, up 11% from a year ago.
NUPLAZID Sales: Reported $159.7 million in revenue for NUPLAZID in Q1 2025, up 23% from the prior year.
International Expansion: Plans for a strong launch of DAYBUE outside the U.S. pending EMA approval in Q1 2026.
Distribution Agreements: Entered into agreements for named patient access in Latin America, Middle East, Asia Pacific, and other regions.
Patient Engagement: Achieved an all-time record of 954 unique patients receiving DAYBUE shipments.
Field Force Expansion: Completed planned hires for the expanded customer model to drive DAYBUE sales growth.
R&D Pipeline: Accelerated timeline for COMPASS PWS Phase 3 study results expected by Q4 2025.
Consumer Activation Campaigns: Continued efforts to increase awareness and diagnosis of Parkinson’s disease psychosis.
Regulatory Issues: The marketing authorization application for trofinetide in the EU is under review, with anticipated approval in Q1 2026. There are ongoing engagements with the PMDA in Japan, which are productive, and orphan drug designation has been received.
Supply Chain Challenges: There is uncertainty around potential tariffs affecting both NUPLAZID and DAYBUE, although the company has substantial inventory on hand to meet anticipated demand.
Economic Factors: The impact of the Medicare Part D redesign has affected net pricing for DAYBUE and NUPLAZID, with adjustments leading to fluctuations in gross to net pricing.
Competitive Pressures: The company faces competition in the Parkinson’s disease psychosis market, with efforts to increase awareness and diagnosis among patients to ensure NUPLAZID is recognized as a first-line therapy.
R&D Challenges: ACADIA has concluded that there is no viable path forward for certain programs, specifically the Rett and Undisclosed Programs, leading to a winding down of efforts.
DAYBUE Sales Growth: First quarter sales were $84.6 million, up 11% from a year ago, with a record number of unique patients served.
NUPLAZID Sales Growth: NUPLAZID achieved first quarter sales of $159.7 million, representing 23% revenue growth year over year.
Expansion Plans: Plans to expand DAYBUE's market presence outside the U.S. with a focus on Europe, anticipating EMA approval in Q1 2026.
R&D Pipeline Updates: COMPASS PWS Phase 3 study results expected by Q4 2025, with potential regulatory submission in Q1 2026.
Consumer Activation Campaigns: Continued focus on consumer engagement to drive awareness and treatment of Parkinson’s disease psychosis.
2025 Revenue Guidance: Reiterating full year 2025 financial guidance with total revenue expected to grow.
R&D Expense Guidance: Expecting R&D expenses to be between $330 million to $350 million, up from prior guidance of $310 million to $330 million.
Inventory Management: Substantial inventory on hand for both NUPLAZID and DAYBUE, sufficient to meet demand into the mid to late 2030s.
Share Repurchase Program: None
The earnings call summary presents a mixed picture: strong revenue growth and optimistic guidance, particularly for NUPLAZID, contrast with increased R&D and SG&A expenses. The absence of a share repurchase program and unresolved regulatory and competitive challenges add uncertainty. The Q&A section reveals confidence in future pricing and product success, but also highlights risks in regulatory approval and market competition. Given the market cap of approximately $2.7 billion, the overall sentiment suggests a neutral stock price movement in the near term.
The earnings call summary presents a mixed picture. Financial performance shows positive revenue growth but increased expenses. The Q&A highlights potential risks, such as regulatory and competitive pressures, and management's lack of clarity on certain issues. Despite the optimistic guidance and strong revenue growth, the absence of shareholder return plans and increased R&D expenses temper enthusiasm. Given the market cap, the stock is likely to remain stable, resulting in a neutral prediction.
The earnings call summary indicates strong financial performance with significant year-over-year sales growth for both DAYBUE and NUPLAZID. The company is in a strong financial position with a substantial cash balance and no debt, which supports future growth and potential shareholder returns. Although there is a lowered guidance for DAYBUE, the increased guidance for NUPLAZID and the sale of a priority review voucher enhance the positive sentiment. The Q&A section reveals some uncertainties, but overall, the financial metrics and strategic initiatives suggest a positive stock price movement.
The earnings call reveals strong financial performance with a 46% increase in net sales, driven by DAYBUE and NUPLAZID. Despite lowered guidance for DAYBUE, optimistic guidance and strategic initiatives like DTC campaigns and pipeline advancements are highlighted. The Q&A section indicates confidence in future growth and addresses operational strategies. The lack of share buybacks or dividends is offset by robust cash flow. Considering the market cap, the stock is likely to experience a positive movement of 2% to 8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
